Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haluska

Showing results (271-280 of 366) with videos related to

Pageof 37
Sort By:
Cancer Research|November 2, 2011
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancerXiaonan Hou, Fei Huang, Luciana F Macedo, et al.
Neuro-Oncology|December 18, 2010
Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytolEdit Dósa, Daniel J Guillaume, Marianne Haluska, et al.
Journal of the American Academy of Dermatology|September 27, 2003
Skin cancer prevention and detection practices among siblings of patients with melanomaAlan C Geller, Karen Emmons, Daniel R Brooks, et al.
Leukemia & Lymphoma|September 6, 2007
Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphomaNancy D Doolittle, Kristoph Jahnke, Richard Belanger, et al.
Cancer|March 13, 2014
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled studyAlexis D Leal, Rui Qin, Pamela J Atherton, et al.
British Journal of Cancer|February 14, 2013
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trialN Colombo, D S McMeekin, P E Schwartz, et al.
Cancer Research|July 1, 1995
Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progressionJ A Reed, F Loganzo, C R Shea, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupAgop Y Bedikian, Michael Millward, Hubert Pehamberger, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.
Pageof 37

Showing results (271-280 of 366) with videos related to

Sort By:
Pageof 37
Cancer Research|November 2, 2011
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancerXiaonan Hou, Fei Huang, Luciana F Macedo, et al.
Neuro-Oncology|December 18, 2010
Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytolEdit Dósa, Daniel J Guillaume, Marianne Haluska, et al.
Journal of the American Academy of Dermatology|September 27, 2003
Skin cancer prevention and detection practices among siblings of patients with melanomaAlan C Geller, Karen Emmons, Daniel R Brooks, et al.
Leukemia & Lymphoma|September 6, 2007
Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphomaNancy D Doolittle, Kristoph Jahnke, Richard Belanger, et al.
Cancer|March 13, 2014
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled studyAlexis D Leal, Rui Qin, Pamela J Atherton, et al.
British Journal of Cancer|February 14, 2013
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trialN Colombo, D S McMeekin, P E Schwartz, et al.
Cancer Research|July 1, 1995
Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progressionJ A Reed, F Loganzo, C R Shea, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupAgop Y Bedikian, Michael Millward, Hubert Pehamberger, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.
Pageof 37